Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 127

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 127
---
6-K subsequently submitted
by us to the SEC prior to the termination of the offering by identifying in such Forms 6-K that they, or certain parts of their contents,
are being incorporated by reference herein, and any Forms 6-K so identified shall be deemed to be incorporated by reference in this prospectus
and to be a part hereof from the date of submission of such documents. Any statement contained in a document incorporated or deemed to
be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a
statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference
herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this prospectus.

The information we incorporate by reference is
an important part of this prospectus, and later information that we file with the SEC will automatically update and supersede the information
contained in this prospectus.

We will provide you without charge, upon your written
or oral request, a copy of any of the documents incorporated by reference in this prospectus, other than exhibits to such documents which
are not specifically incorporated by reference into such documents. Please direct your written or telephone requests to us at: NLS Pharmaceutics
Ltd., The Circle 6, 8058 Zurich, Switzerland. Our telephone number in Switzerland is +41.44.512.2150.

<div align='center'>87

WHERE YOU CAN FIND ADDITIONAL INFORMATION</div>

We are a Swiss company and are a “foreign
private issuer” as defined in Rule 3b-4 under the Exchange Act. As a foreign private issuer, we are exempt from the rules under
the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are
exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.

In addition, we are not required under the Exchange
Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. companies
whose securities are registered under the Exchange Act. However, we file with the SEC, within 120 days after the end of each fiscal year,
or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent